Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 355

1.

HPA axis in psychotic major depression and schizophrenia spectrum disorders: Cortisol, clinical symptomatology, and cognition.

Cherian K, Schatzberg AF, Keller J.

Schizophr Res. 2019 Jul 12. pii: S0920-9964(19)30266-X. doi: 10.1016/j.schres.2019.07.003. [Epub ahead of print]

PMID:
31307859
2.

A Word to the Wise About Intranasal Esketamine.

Schatzberg AF.

Am J Psychiatry. 2019 Jun 1;176(6):422-424. doi: 10.1176/appi.ajp.2019.19040423. Epub 2019 May 21. No abstract available.

PMID:
31109197
3.

Genome-wide association study identifies 30 loci associated with bipolar disorder.

Stahl EA, Breen G, Forstner AJ, McQuillin A, Ripke S, Trubetskoy V, Mattheisen M, Wang Y, Coleman JRI, Gaspar HA, de Leeuw CA, Steinberg S, Pavlides JMW, Trzaskowski M, Byrne EM, Pers TH, Holmans PA, Richards AL, Abbott L, Agerbo E, Akil H, Albani D, Alliey-Rodriguez N, Als TD, Anjorin A, Antilla V, Awasthi S, Badner JA, Bækvad-Hansen M, Barchas JD, Bass N, Bauer M, Belliveau R, Bergen SE, Pedersen CB, Bøen E, Boks MP, Boocock J, Budde M, Bunney W, Burmeister M, Bybjerg-Grauholm J, Byerley W, Casas M, Cerrato F, Cervantes P, Chambert K, Charney AW, Chen D, Churchhouse C, Clarke TK, Coryell W, Craig DW, Cruceanu C, Curtis D, Czerski PM, Dale AM, de Jong S, Degenhardt F, Del-Favero J, DePaulo JR, Djurovic S, Dobbyn AL, Dumont A, Elvsåshagen T, Escott-Price V, Fan CC, Fischer SB, Flickinger M, Foroud TM, Forty L, Frank J, Fraser C, Freimer NB, Frisén L, Gade K, Gage D, Garnham J, Giambartolomei C, Pedersen MG, Goldstein J, Gordon SD, Gordon-Smith K, Green EK, Green MJ, Greenwood TA, Grove J, Guan W, Guzman-Parra J, Hamshere ML, Hautzinger M, Heilbronner U, Herms S, Hipolito M, Hoffmann P, Holland D, Huckins L, Jamain S, Johnson JS, Juréus A, Kandaswamy R, Karlsson R, Kennedy JL, Kittel-Schneider S, Knowles JA, Kogevinas M, Koller AC, Kupka R, Lavebratt C, Lawrence J, Lawson WB, Leber M, Lee PH, Levy SE, Li JZ, Liu C, Lucae S, Maaser A, MacIntyre DJ, Mahon PB, Maier W, Martinsson L, McCarroll S, McGuffin P, McInnis MG, McKay JD, Medeiros H, Medland SE, Meng F, Milani L, Montgomery GW, Morris DW, Mühleisen TW, Mullins N, Nguyen H, Nievergelt CM, Adolfsson AN, Nwulia EA, O'Donovan C, Loohuis LMO, Ori APS, Oruc L, Ösby U, Perlis RH, Perry A, Pfennig A, Potash JB, Purcell SM, Regeer EJ, Reif A, Reinbold CS, Rice JP, Rivas F, Rivera M, Roussos P, Ruderfer DM, Ryu E, Sánchez-Mora C, Schatzberg AF, Scheftner WA, Schork NJ, Shannon Weickert C, Shehktman T, Shilling PD, Sigurdsson E, Slaney C, Smeland OB, Sobell JL, Søholm Hansen C, Spijker AT, St Clair D, Steffens M, Strauss JS, Streit F, Strohmaier J, Szelinger S, Thompson RC, Thorgeirsson TE, Treutlein J, Vedder H, Wang W, Watson SJ, Weickert TW, Witt SH, Xi S, Xu W, Young AH, Zandi P, Zhang P, Zöllner S; eQTLGen Consortium; BIOS Consortium, Adolfsson R, Agartz I, Alda M, Backlund L, Baune BT, Bellivier F, Berrettini WH, Biernacka JM, Blackwood DHR, Boehnke M, Børglum AD, Corvin A, Craddock N, Daly MJ, Dannlowski U, Esko T, Etain B, Frye M, Fullerton JM, Gershon ES, Gill M, Goes F, Grigoroiu-Serbanescu M, Hauser J, Hougaard DM, Hultman CM, Jones I, Jones LA, Kahn RS, Kirov G, Landén M, Leboyer M, Lewis CM, Li QS, Lissowska J, Martin NG, Mayoral F, McElroy SL, McIntosh AM, McMahon FJ, Melle I, Metspalu A, Mitchell PB, Morken G, Mors O, Mortensen PB, Müller-Myhsok B, Myers RM, Neale BM, Nimgaonkar V, Nordentoft M, Nöthen MM, O'Donovan MC, Oedegaard KJ, Owen MJ, Paciga SA, Pato C, Pato MT, Posthuma D, Ramos-Quiroga JA, Ribasés M, Rietschel M, Rouleau GA, Schalling M, Schofield PR, Schulze TG, Serretti A, Smoller JW, Stefansson H, Stefansson K, Stordal E, Sullivan PF, Turecki G, Vaaler AE, Vieta E, Vincent JB, Werge T, Nurnberger JI, Wray NR, Di Florio A, Edenberg HJ, Cichon S, Ophoff RA, Scott LJ, Andreassen OA, Kelsoe J, Sklar P; Bipolar Disorder Working Group of the Psychiatric Genomics Consortium.

Nat Genet. 2019 May;51(5):793-803. doi: 10.1038/s41588-019-0397-8. Epub 2019 May 1.

PMID:
31043756
4.

Rigorous Trial Design Is Essential to Understand the Role of Opioid Receptors in Ketamine's Antidepressant Effect.

Heifets BD, Williams NR, Bentzley BS, Schatzberg AF.

JAMA Psychiatry. 2019 Jun 1;76(6):657-658. doi: 10.1001/jamapsychiatry.2019.0766. No abstract available.

PMID:
31042274
5.

Scientific Issues Relevant to Improving the Diagnosis, Risk Assessment, and Treatment of Major Depression.

Schatzberg AF.

Am J Psychiatry. 2019 May 1;176(5):342-347. doi: 10.1176/appi.ajp.2019.19030273.

PMID:
31039643
6.

Rigorous Translational Models Are Key to Studying Ketamine's Antidepressant Mechanism: Response to Wang and Kaplin.

Heifets BD, Williams NR, Blasey C, Sudheimer K, Rodriguez CI, Schatzberg AF.

Am J Psychiatry. 2019 May 1;176(5):412. doi: 10.1176/appi.ajp.2019.19010044r. No abstract available.

PMID:
31039633
7.

Splice-Break: exploiting an RNA-seq splice junction algorithm to discover mitochondrial DNA deletion breakpoints and analyses of psychiatric disorders.

Hjelm BE, Rollins B, Morgan L, Sequeira A, Mamdani F, Pereira F, Damas J, Webb MG, Weber MD, Schatzberg AF, Barchas JD, Lee FS, Akil H, Watson SJ, Myers RM, Chao EC, Kimonis V, Thompson PM, Bunney WE, Vawter MP.

Nucleic Acids Res. 2019 Jun 4;47(10):e59. doi: 10.1093/nar/gkz164.

8.

Interpreting Ketamine's Opioid Receptor Dependent Effect: Response to Sanacora.

Heifets BD, Williams NR, Blasey C, Sudheimer K, Rodriguez CI, Schatzberg AF.

Am J Psychiatry. 2019 Mar 1;176(3):249-250. doi: 10.1176/appi.ajp.2018.18091061r. No abstract available.

PMID:
30818991
9.

Target Population, Dose, and Timing Considerations for Understanding Naltrexone's Subjective Effect: Response to Amiaz.

Heifets BD, Williams NR, Blasey C, Sudheimer K, Rodriguez CI, Schatzberg AF.

Am J Psychiatry. 2019 Mar 1;176(3):251-252. doi: 10.1176/appi.ajp.2018.18111231r. No abstract available.

PMID:
30818989
10.

Prefrontal networks dynamically related to recovery from major depressive disorder: a longitudinal pharmacological fMRI study.

Meyer BM, Rabl U, Huemer J, Bartova L, Kalcher K, Provenzano J, Brandner C, Sezen P, Kasper S, Schatzberg AF, Moser E, Chen G, Pezawas L.

Transl Psychiatry. 2019 Feb 4;9(1):64. doi: 10.1038/s41398-019-0395-8.

11.

Correction: Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD).

Fava M, Freeman MP, Flynn M, Judge H, Hoeppner BB, Cusin C, Ionescu DF, Mathew SJ, Chang LC, Iosifescu DV, Murrough J, Debattista C, Schatzberg AF, Trivedi MH, Jha MK, Sanacora G, Wilkinson ST, Papakostas GI.

Mol Psychiatry. 2019 Jan 7. doi: 10.1038/s41380-018-0311-2. [Epub ahead of print]

PMID:
30617276
12.

Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD).

Fava M, Freeman MP, Flynn M, Judge H, Hoeppner BB, Cusin C, Ionescu DF, Mathew SJ, Chang LC, Iosifescu DV, Murrough J, Debattista C, Schatzberg AF, Trivedi MH, Jha MK, Sanacora G, Wilkinson ST, Papakostas GI.

Mol Psychiatry. 2018 Oct 3. doi: 10.1038/s41380-018-0256-5. [Epub ahead of print] Erratum in: Mol Psychiatry. 2019 Jan 7;:.

13.

Diagnostic differences in verbal learning strategies and verbal memory in patients with mood disorders and psychotic disorders.

Gill SK, Gomez RG, Keller J, Schatzberg AF.

Psychiatry Res. 2018 Nov;269:733-739. doi: 10.1016/j.psychres.2018.09.003. Epub 2018 Sep 5.

PMID:
30273898
14.

Attenuation of Antidepressant Effects of Ketamine by Opioid Receptor Antagonism.

Williams NR, Heifets BD, Blasey C, Sudheimer K, Pannu J, Pankow H, Hawkins J, Birnbaum J, Lyons DM, Rodriguez CI, Schatzberg AF.

Am J Psychiatry. 2018 Dec 1;175(12):1205-1215. doi: 10.1176/appi.ajp.2018.18020138. Epub 2018 Aug 29.

15.

Cognitive effects of mifepristone in overweight, euthymic adults with depressive disorders.

Roat-Shumway S, Wroolie TE, Watson K, Schatzberg AF, Rasgon NL.

J Affect Disord. 2018 Oct 15;239:242-246. doi: 10.1016/j.jad.2018.07.014. Epub 2018 Jul 10.

PMID:
30025313
16.

Inference of cell type content from human brain transcriptomic datasets illuminates the effects of age, manner of death, dissection, and psychiatric diagnosis.

Hagenauer MH, Schulmann A, Li JZ, Vawter MP, Walsh DM, Thompson RC, Turner CA, Bunney WE, Myers RM, Barchas JD, Schatzberg AF, Watson SJ, Akil H.

PLoS One. 2018 Jul 17;13(7):e0200003. doi: 10.1371/journal.pone.0200003. eCollection 2018.

17.

Learning to actively cope with stress in female mice.

Lyons DM, Buckmaster CL, Schatzberg AF.

Psychoneuroendocrinology. 2018 Oct;96:78-83. doi: 10.1016/j.psyneuen.2018.06.010. Epub 2018 Jun 9.

PMID:
29909293
18.

Connective Tissue Growth Factor Is a Novel Prodepressant.

Turner CA, Sharma V, Hagenauer MH, Chaudhury S, O'Connor AM, Hebda-Bauer EK, Thompson RC, Myers RM, Bunney WE, Barchas JD, Lee FS, Schatzberg AF, Watson SJ Jr, Akil H.

Biol Psychiatry. 2018 Oct 15;84(8):555-562. doi: 10.1016/j.biopsych.2018.04.013. Epub 2018 May 3.

19.

Neural cell adhesion molecule peptide mimetics modulate emotionality: pharmacokinetic and behavioral studies in rats and non-human primates.

Turner CA, Lyons DM, Buckmaster CL, Aurbach EL, Watson SJ, Schatzberg AF, Akil H.

Neuropsychopharmacology. 2019 Jan;44(2):356-363. doi: 10.1038/s41386-018-0052-6. Epub 2018 Apr 9.

PMID:
29703997
20.

Mitochondrial Complex I Deficiency in Schizophrenia and Bipolar Disorder and Medication Influence.

Rollins BL, Morgan L, Hjelm BE, Sequeira A, Schatzberg AF, Barchas JD, Lee FS, Myers RM, Watson SJ, Akil H, Potkin SG, Bunney WE, Vawter MP.

Mol Neuropsychiatry. 2018 Feb;3(3):157-169. doi: 10.1159/000484348. Epub 2017 Nov 30.

21.

High-dose spaced theta-burst TMS as a rapid-acting antidepressant in highly refractory depression.

Williams NR, Sudheimer KD, Bentzley BS, Pannu J, Stimpson KH, Duvio D, Cherian K, Hawkins J, Scherrer KH, Vyssoki B, DeSouza D, Raj KS, Keller J, Schatzberg AF.

Brain. 2018 Mar 1;141(3):e18. doi: 10.1093/brain/awx379. No abstract available.

22.

The Black Book of Psychotropic Dosing and Monitoring.

Schatzberg AF, Charles D.

Psychopharmacol Bull. 2018 Jan 15;48(1):64-153. Review. No abstract available.

23.

Corticotropin-releasing factor 1 receptor haplotype and cognitive features of major depression.

Davis EG, Keller J, Hallmayer J, Pankow HR, Murphy GM Jr, Gotlib IH, Schatzberg AF.

Transl Psychiatry. 2018 Jan 10;8(1):5. doi: 10.1038/s41398-017-0051-0. Review.

24.

Quantitative validation of immunofluorescence and lectin staining using reduced CLARITY acrylamide formulations.

Krolewski DM, Kumar V, Martin B, Tomer R, Deisseroth K, Myers RM, Schatzberg AF, Lee FS, Barchas JD, Bunney WE, Akil H, Watson SJ Jr.

Brain Struct Funct. 2018 Mar;223(2):987-999. doi: 10.1007/s00429-017-1583-z. Epub 2017 Dec 14.

25.

Antidepressant Outcomes Predicted by Genetic Variation in Corticotropin-Releasing Hormone Binding Protein.

O'Connell CP, Goldstein-Piekarski AN, Nemeroff CB, Schatzberg AF, Debattista C, Carrillo-Roa T, Binder EB, Dunlop BW, Craighead WE, Mayberg HS, Williams LM.

Am J Psychiatry. 2018 Mar 1;175(3):251-261. doi: 10.1176/appi.ajp.2017.17020172. Epub 2017 Dec 15.

26.

Stress amplifies sex differences in primate prefrontal profiles of gene expression.

Lee AG, Hagenauer M, Absher D, Morrison KE, Bale TL, Myers RM, Watson SJ, Akil H, Schatzberg AF, Lyons DM.

Biol Sex Differ. 2017 Nov 2;8(1):36. doi: 10.1186/s13293-017-0157-3.

27.

Post-mortem molecular profiling of three psychiatric disorders.

Ramaker RC, Bowling KM, Lasseigne BN, Hagenauer MH, Hardigan AA, Davis NS, Gertz J, Cartagena PM, Walsh DM, Vawter MP, Jones EG, Schatzberg AF, Barchas JD, Watson SJ, Bunney BG, Akil H, Bunney WE, Li JZ, Cooper SJ, Myers RM.

Genome Med. 2017 Jul 28;9(1):72. doi: 10.1186/s13073-017-0458-5.

28.

A Consensus Statement on the Use of Ketamine in the Treatment of Mood Disorders.

Sanacora G, Frye MA, McDonald W, Mathew SJ, Turner MS, Schatzberg AF, Summergrad P, Nemeroff CB; American Psychiatric Association (APA) Council of Research Task Force on Novel Biomarkers and Treatments.

JAMA Psychiatry. 2017 Apr 1;74(4):399-405. doi: 10.1001/jamapsychiatry.2017.0080. Review.

PMID:
28249076
29.

Erratum: Resting-state connectivity biomarkers define neurophysiological subtypes of depression.

Drysdale AT, Grosenick L, Downar J, Dunlop K, Mansouri F, Meng Y, Fetcho RN, Zebley B, Oathes DJ, Etkin A, Schatzberg AF, Sudheimer K, Keller J, Mayberg HS, Gunning FM, Alexopoulos GS, Fox MD, Pascual-Leone A, Voss HU, Casey BJ, Dubin MJ, Liston C.

Nat Med. 2017 Feb 7;23(2):264. doi: 10.1038/nm0217-264d. No abstract available.

30.

Side Effects to Antidepressant Treatment in Patients With Depression and Comorbid Panic Disorder.

Shankman SA, Gorka SM, Katz AC, Klein DN, Markowitz JC, Arnow BA, Manber R, Rothbaum BO, Thase ME, Schatzberg AF, Keller MB, Trivedi MH, Kocsis JH.

J Clin Psychiatry. 2017 Apr;78(4):433-440. doi: 10.4088/JCP.15m10370.

PMID:
28068460
31.

Striatal dopamine D2/3 receptor regulation by stress inoculation in squirrel monkeys.

Lee AG, Nechvatal JM, Shen B, Buckmaster CL, Levy MJ, Chin FT, Schatzberg AF, Lyons DM.

Neurobiol Stress. 2016 Feb 8;3:68-73. eCollection 2016 Jun.

32.

Variable telomere length across post-mortem human brain regions and specific reduction in the hippocampus of major depressive disorder.

Mamdani F, Rollins B, Morgan L, Myers RM, Barchas JD, Schatzberg AF, Watson SJ, Akil H, Potkin SG, Bunney WE, Vawter MP, Sequeira PA.

Transl Psychiatry. 2016 Dec 6;6(12):e969. doi: 10.1038/tp.2015.164. No abstract available.

33.

Resting-state connectivity biomarkers define neurophysiological subtypes of depression.

Drysdale AT, Grosenick L, Downar J, Dunlop K, Mansouri F, Meng Y, Fetcho RN, Zebley B, Oathes DJ, Etkin A, Schatzberg AF, Sudheimer K, Keller J, Mayberg HS, Gunning FM, Alexopoulos GS, Fox MD, Pascual-Leone A, Voss HU, Casey BJ, Dubin MJ, Liston C.

Nat Med. 2017 Jan;23(1):28-38. doi: 10.1038/nm.4246. Epub 2016 Dec 5. Erratum in: Nat Med. 2017 Feb 7;23 (2):264.

34.

Eberhard H Uhlenhuth.

Schatzberg AF, Keith SJ.

Neuropsychopharmacology. 2016 Dec;41(13):3127. doi: 10.1038/npp.2016.132. No abstract available.

35.

Human amygdala engagement moderated by early life stress exposure is a biobehavioral target for predicting recovery on antidepressants.

Goldstein-Piekarski AN, Korgaonkar MS, Green E, Suppes T, Schatzberg AF, Hastie T, Nemeroff CB, Williams LM.

Proc Natl Acad Sci U S A. 2016 Oct 18;113(42):11955-11960. Epub 2016 Oct 10.

36.

Major depressive disorder.

Otte C, Gold SM, Penninx BW, Pariante CM, Etkin A, Fava M, Mohr DC, Schatzberg AF.

Nat Rev Dis Primers. 2016 Sep 15;2:16065. doi: 10.1038/nrdp.2016.65. Review.

PMID:
27629598
37.

HPA axis in major depression: cortisol, clinical symptomatology and genetic variation predict cognition.

Keller J, Gomez R, Williams G, Lembke A, Lazzeroni L, Murphy GM Jr, Schatzberg AF.

Mol Psychiatry. 2017 Apr;22(4):527-536. doi: 10.1038/mp.2016.120. Epub 2016 Aug 16.

38.

The microRNA network is altered in anterior cingulate cortex of patients with unipolar and bipolar depression.

Azevedo JA, Carter BS, Meng F, Turner DL, Dai M, Schatzberg AF, Barchas JD, Jones EG, Bunney WE, Myers RM, Akil H, Watson SJ, Thompson RC.

J Psychiatr Res. 2016 Nov;82:58-67. doi: 10.1016/j.jpsychires.2016.07.012. Epub 2016 Jul 18.

39.

WHITHER KETAMINE AS AN ANTIDEPRESSANT: PANACEA OR TOXIN?

Newport DJ, Schatzberg AF, Nemeroff CB.

Depress Anxiety. 2016 Aug;33(8):685-8. doi: 10.1002/da.22535. No abstract available.

PMID:
27459676
40.

Constance E. Lieber, Theodore R. Stanley, and the Enduring Impact of Philanthropy on Psychiatry Research.

Krystal JH, Abi-Dargham A, Akbarian S, Arnsten AFT, Barch DM, Bearden CE, Braff DL, Brown ES, Bullmore ET, Carlezon WA Jr, Carter CS, Cook EH Jr, Daskalakis ZJ, DiLeone RJ, Duman RS, Grace AA, Hariri AR, Harrison PJ, Hiroi N, Kenny PJ, Kleinman JE, Krystal AD, Lewis DA, Lipska BK, Marder SR, Mason GF, Mathalon DH, McClung CA, McDougle CJ, McIntosh AM, McMahon FJ, Mirnics K, Monteggia LM, Narendran R, Nestler EJ, Neumeister A, O'Donovan MC, Öngür D, Pariante CM, Paulus MP, Pearlson G, Phillips ML, Pine DS, Pizzagalli DA, Pletnikov MV, Ragland JD, Rapoport JL, Ressler KJ, Russo SJ, Sanacora G, Sawa A, Schatzberg AF, Shaham Y, Shamay-Tsoory SG, Sklar P, State MW, Stein MB, Strakowski SM, Taylor SF, Turecki G, Turetsky BI, Weissman MM, Zachariou V, Zarate CA Jr, Zubieta JK.

Biol Psychiatry. 2016 Jul 15;80(2):84-86. doi: 10.1016/j.biopsych.2016.05.004. No abstract available.

41.

Anhedonia and general distress show dissociable ventromedial prefrontal cortex connectivity in major depressive disorder.

Young CB, Chen T, Nusslock R, Keller J, Schatzberg AF, Menon V.

Transl Psychiatry. 2016 May 17;6:e810. doi: 10.1038/tp.2016.80.

42.

Childhood trauma predicts antidepressant response in adults with major depression: data from the randomized international study to predict optimized treatment for depression.

Williams LM, Debattista C, Duchemin AM, Schatzberg AF, Nemeroff CB.

Transl Psychiatry. 2016 May 3;6:e799. doi: 10.1038/tp.2016.61.

43.

Learning to cope with stress modulates anterior cingulate cortex stargazin expression in monkeys and mice.

Lee AG, Capanzana R, Brockhurst J, Cheng MY, Buckmaster CL, Absher D, Schatzberg AF, Lyons DM.

Neurobiol Learn Mem. 2016 May;131:95-100. doi: 10.1016/j.nlm.2016.03.015. Epub 2016 Mar 18.

44.

Quantitative Trait Locus and Brain Expression of HLA-DPA1 Offers Evidence of Shared Immune Alterations in Psychiatric Disorders.

Morgan LZ, Rollins B, Sequeira A, Byerley W, DeLisi LE, Schatzberg AF, Barchas JD, Myers RM, Watson SJ, Akil H, Bunney WE Jr, Vawter MP.

Microarrays (Basel). 2016 Mar;5(1). pii: 6. Epub 2016 Mar 7.

45.

Developing a clinical translational neuroscience taxonomy for anxiety and mood disorder: protocol for the baseline-follow up Research domain criteria Anxiety and Depression ("RAD") project.

Williams LM, Goldstein-Piekarski AN, Chowdhry N, Grisanzio KA, Haug NA, Samara Z, Etkin A, O'Hara R, Schatzberg AF, Suppes T, Yesavage J.

BMC Psychiatry. 2016 Mar 15;16:68. doi: 10.1186/s12888-016-0771-3.

46.

NMDA antagonist treatment of depression.

Williams NR, Schatzberg AF.

Curr Opin Neurobiol. 2016 Feb;36:112-7. doi: 10.1016/j.conb.2015.11.001. Epub 2015 Dec 11. Review.

PMID:
26687375
47.

Opioids in Psychiatric Disorders: Back to the Future?

Schatzberg AF.

Am J Psychiatry. 2016 Jun 1;173(6):564-5. doi: 10.1176/appi.ajp.2015.15101354. Epub 2015 Dec 18. No abstract available.

PMID:
26684924
48.

Variable telomere length across post-mortem human brain regions and specific reduction in the hippocampus of major depressive disorder.

Mamdani F, Rollins B, Morgan L, Myers RM, Barchas JD, Schatzberg AF, Watson SJ, Akil H, Potkin SG, Bunney WE, Vawter MP, Sequeira PA.

Transl Psychiatry. 2015 Sep 15;5:e636. doi: 10.1038/tp.2015.134. Erratum in: Transl Psychiatry. 2016 Dec 6;6(12 ):e969.

49.

Fibroblast growth factor 9 is a novel modulator of negative affect.

Aurbach EL, Inui EG, Turner CA, Hagenauer MH, Prater KE, Li JZ, Absher D, Shah N, Blandino P Jr, Bunney WE, Myers RM, Barchas JD, Schatzberg AF, Watson SJ Jr, Akil H.

Proc Natl Acad Sci U S A. 2015 Sep 22;112(38):11953-8. doi: 10.1073/pnas.1510456112. Epub 2015 Sep 8.

50.

Development of New Psychopharmacological Agents for Depression and Anxiety.

Schatzberg AF.

Psychiatr Clin North Am. 2015 Sep;38(3):379-93. doi: 10.1016/j.psc.2015.05.009. Review.

PMID:
26300029

Supplemental Content

Loading ...
Support Center